Ru(III) Nanocomplex for ctDNA Targeting and Antimicrobial Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medicinal treatments for cancer and microbial infections lack effective small molecules that can target specific sequences in circulating tumor DNA and exhibit broad therapeutic activities, including antibacterial, antifungal, antiviral, and antioxidant effects.
Innovation Solution
A novel nano-sized [4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex is synthesized by reacting Ruthenium (III) chloride with the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine ligand and phenanthroline, forming nanoparticles with potential therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional small molecule drugs are used, then they can be administered easily, but they lack the ability to target specific sequences in circulating tumor DNA and show limited therapeutic activity
Solution Approach 1:
The patent creates a hybrid nanostructure combining a Ru(III) metal complex core with a DNAzyme functional layer. This composite structure integrates the targeting capability of DNA sequences with the therapeutic activity of metal-based drugs, achieving both specific ctDNA targeting and potent anticancer activity that conventional small molecules cannot provide.
2Reliability
If nano-sized complexes are synthesized to enhance therapeutic activity, then broad therapeutic effects are achieved, but the synthesis process becomes more complex
Solution Approach 1:
The patent pre-synthesizes the organic ligand (4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine) with specific functional groups designed to coordinate with Ru(III) ions. This preliminary preparation of the ligand structure with built-in coordination sites simplifies the subsequent complex formation step, making the overall nanocomplex synthesis more straightforward despite the advanced functionality achieved.
3Adaptability or versatility
If single-function drugs are used, then the treatment approach is simple, but they cannot address multiple diseases including cancer, bacterial infections, fungal infections, and viral infections simultaneously
Solution Approach 1:
The patent designs a multi-functional nanotherapeutic platform where the Ru(III) complex core provides anticancer activity while the DNAzyme layer enables recognition of circulating tumor DNA. This single nanocomplex structure is engineered to potentially address multiple therapeutic needs including cancer treatment, antibacterial, antifungal, and antiviral activities, replacing the need for multiple separate drugs.
4Reliability
If standard drugs are used, then they have established safety profiles, but they lack antioxidant properties and broad-spectrum antimicrobial activity
Solution Approach 1:
The patent alters the chemical and functional parameters of the therapeutic agent by transitioning from conventional small molecule drugs to a metal-based nanocomplex with DNAzyme functionality. This parameter change introduces new properties including antioxidant activity, enhanced antimicrobial effects, and the ability to target specific DNA sequences, thereby increasing resistance to various harmful factors including pathogens and oxidative stress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex demonstrates potent anticancer activity against breast cancer cells, significant antibacterial and antifungal effects against E. coli and Aspergillus flavus, and strong antioxidant properties, offering a promising pharmaceutical agent for various therapeutic uses.
Implementation Method 1
the coordination chemistry of biologically active chelates
Implementation Method 2
promoting an antioxidant effect in a patient
Data Source
AI summary
A compound 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex, its synthesis, and its use for pharmaceutical applications.